US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...

Researchers are slowly tossing much of what we've been told for many years about Alzheimer's disease out the window — and replacing what has been a very dreary tale with new findings.

When Patty Norman first noticed concerns about her memory, she and her husband, Tommy Norman, faced uncertainty about what ...

From AI-powered drug discovery to regenerative therapies and next-generation neurology tools, Mayo Clinic researchers made significant strides in 2025 toward predicting, preventing and treating some o ...

Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...

Alzheimer's disease affects the brain in tragic and seemingly irreversible ways, but a new study gives hope that its ...

FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.

The biopharmaceutical company accepted for filing a supplemental new drug application for AXS-05 to treat Alzheimer's disease agitation, and has granted the application priority review designation, ...

A breakthrough new Alzheimer’s disease treatment is stopping neurodegeneration in its tracks, even before symptoms appear.

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...

Axsome Therapeutics (AXSM) stock gains as the FDA grants priority review to expand its depression drug Auvelity for Alzheimer ...

Scientists at Johns Hopkins Medicine say results of a new National Institutes of Health-funded study are advancing efforts to ...